hiPSC-CM在中药早期心脏毒性筛选和上市后安全性再评价中的应用展望

Application potentials of hiPSC-derived cardiomyocytes in preclinical cardiotoxicity screening and post-marketing safety reevaluation of Chinese medicine

药物研发失败的重要原因之一是由于其心脏毒性,与单体西药相比,基于复方的中药心脏毒性评估面临着更大的挑战。人诱导多能干细胞分化的心肌细胞(hiPSC-CM)相当于幼稚型心肌细胞,而且可以无限增殖,将为生物医学带来革命性变化。通过查阅PubMed、中国知网数据库搜集相关文献,就目前基于hiPSC-CM的心脏毒性高通量药物筛选方法进行综述,并对其在创新中药研发和上市中药安全性再评价的应用潜力予以分析和展望。

Cardiotoxicity is one of the leading causes for drug failure. Compared with the western medicine, cardiotoxicity assessment of traditional Chinese medicine （TCM）,which is composed of two or more ingredients, faces greater challenges. Human induced pluripotent stem cell-derived cardiomyocytes （hiPSC-CM） is equivalent to immature myocardial cells and can proliferate with impunity. It will bring revolutionary change to biomedicine. Based on database of PubMed and CNKI, this review aims to outline the recent progress made in high throughput screening assays for cardiotoxicity assessment and to discuss the potential applications of hiPSC-CM in innovative TCM drug discovery and safety reevaluation of TCM in market.